Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 19Colorectal Neoplasms 11Brain Neoplasms 7Colonic Neoplasms 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 2Lung Neoplasms 2Thyroid Neoplasms 1Solid Tumor 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × encorafenib × Clear all
NCT03898908 2025-05-21

EBRAIN-MEL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed
48 enrolled 24 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡